Beneficial effects of mifepristone treatment in breast cancer patients selected by the progesterone receptor isoform ratio: Results from the MIPRA trial.

Andrés Elía Leo Saldain Silvia I Vanzulli Luisa Alejandra Helguero Caroline A Lamb Victoria Fabris Gabriela Pataccini Paula Martínez-Vazquez Javier Burruchaga Ines Caillet-Bois Eunice Spengler Gabriela Acosta Haab Marcos Liguori Alejandra Castets Silvia Lovisi María F Abascal Virginia Novaro Jana Sánchez Javier Munoz Jose M Belizán Martín Carlos AbbaHugo GassPaola Rojas Claudia Lanari

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Our results support the use of mifepristone in patients with luminal breast cancer with high PRA/PRB ratios. The combined effects of mifepristone and estrogen receptor modulators warrant clinical evaluation to improve endocrine treatment responsiveness in these patients.

Keyphrases

estrogen receptor
end stage renal disease
clinical evaluation
chronic kidney disease
ejection fraction
small molecule
randomized controlled trial
study protocol
peritoneal dialysis
prognostic factors
replacement therapy
double blind